{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T01:06:32Z","timestamp":1783559192359,"version":"3.55.0"},"reference-count":35,"publisher":"Bioscientifica","issue":"1","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"vor","delay-in-days":424,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["journals.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,1,1]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) represents a possible therapeutic option for patients with metastatic inoperable phaeochromocytomas (PCC) and paragangliomas (PGL) who demonstrate adequate somatostatin analogue binding on molecular imaging. We describe treatment outcomes in our cohort of patients stratified according to germline pathogenic variants (PV) in succinate dehydrogenase (SDHx) subunit-encoding genes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this retrospective analysis, we evaluated 20 patients with metastatic PCC\/PGL who underwent two or more cycles of 177Lu-DOTATATE therapy. Clinical, radiological, and biochemical responses were assessed 8\u201312 weeks after the final PRRT cycle. We describe overall treatment efficacy at follow-up after stratifying according to the presence of germline SDHx PV. Radiological progression was quantified based on the sum of the longest diameter (SLD) of the target lesion. Progression-free survival (PFS) and overall survival were estimated using Kaplan\u2013Meier survival analysis. We also aimed to investigate the impact of PRRT on health-related quality of life (HRQoL), as assessed using the EORTC QLQ-GINET21 questionnaire.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>After a median follow-up of 29 months, we confirmed stable disease in 12 patients (60%), a partial response in one (5%), and progressive disease in seven patients (35%). The absolute mean difference in SLD was +5 \u00b1 12 mm for bone lesions, \u22124 \u00b1 6 mm for peritoneal, +8 \u00b1 14 mm for liver lesions and \u22121 \u00b1 5 mm for lymph nodes (paired t-test P-value 0.273, 0.741, 0.208 and 0.826, respectively). Thirteen patients (65%) had received two or more previous lines of treatment. The overall median PFS for the entire cohort, PGL patients, SDHx positive and negative groups was 24 months (95% CI: 9.9\u201338.1), 18 months (95% CI: 8.4\u201327.6), 24 months (95% CI: 11.9\u201336.0) and 18 months (95% CI: 0\u201348), respectively. No grade 3\/4 cytopenia or nephrotoxicity was observed. Overall, HRQoL improved after PRRT, as evidenced by the progressive decline in overall symptom scores in the QLQ-GINET21.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>177Lu-PRRT appears to be an effective therapy with a good safety profile for patients with metastatic PPGL. It also appears to improve HRQoL in patients with metastatic PPGL. Further studies are needed to explore the most effective treatment modalities in this group of patients and their sequencing.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1530\/eo-25-0019","type":"journal-article","created":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T12:47:04Z","timestamp":1758804424000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-15","source":"Crossref","is-referenced-by-count":1,"title":["177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) in metastatic phaeochromocytomas and paragangliomas (mPPGL): a single centre retrospective analysis of experience at an ENETS Centre of Excellence"],"prefix":"10.1530","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7884-0403","authenticated-orcid":true,"given":"Kalyan Mansukhbhai","family":"Shekhda","sequence":"first","affiliation":[{"name":"Neuroendocrine Tumour Unit, ENETS Centre of Excellence, Royal Free Hospital 1 , ,","place":["London, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3310-1521","authenticated-orcid":true,"given":"Eleni","family":"Armeni","sequence":"additional","affiliation":[{"name":"Neuroendocrine Tumour Unit, ENETS Centre of Excellence, Royal Free Hospital 1 , ,","place":["London, UK"]},{"name":"Department of Diabetes and Endocrinology, Royal Free Hospital 2 , ,","place":["London, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0429-7572","authenticated-orcid":true,"given":"Yiwang","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Radiology, Royal Free Hospital 3 , ,","place":["London, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6347-0219","authenticated-orcid":true,"given":"Manfredi","family":"D\u2019afflitto","sequence":"additional","affiliation":[{"name":"Neuroendocrine Tumour Unit, ENETS Centre of Excellence, Royal Free Hospital 1 , ,","place":["London, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4417-7716","authenticated-orcid":true,"given":"Aimee","family":"Hayes","sequence":"additional","affiliation":[{"name":"Neuroendocrine Tumour Unit, ENETS Centre of Excellence, Royal Free Hospital 1 , ,","place":["London, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5237-8641","authenticated-orcid":true,"given":"Dalvinder","family":"Mandair","sequence":"additional","affiliation":[{"name":"Neuroendocrine Tumour Unit, ENETS Centre of Excellence, Royal Free Hospital 1 , ,","place":["London, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominic","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Radiology, Royal Free Hospital 3 , ,","place":["London, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann-Marie","family":"Quigley","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Royal Free Hospital 4 , ,","place":["London, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2886-9691","authenticated-orcid":true,"given":"Shaunak","family":"Navalkissoor","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Royal Free Hospital 4 , ,","place":["London, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4617-9013","authenticated-orcid":true,"given":"Gopinath","family":"Gnanasegaran","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Royal Free Hospital 4 , ,","place":["London, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1176-6186","authenticated-orcid":true,"given":"Ashley B","family":"Grossman","sequence":"additional","affiliation":[{"name":"Neuroendocrine Tumour Unit, ENETS Centre of Excellence, Royal Free Hospital 1 , ,","place":["London, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0177-1352","authenticated-orcid":true,"given":"Martyn","family":"Caplin","sequence":"additional","affiliation":[{"name":"Neuroendocrine Tumour Unit, ENETS Centre of Excellence, Royal Free Hospital 1 , ,","place":["London, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1152-7727","authenticated-orcid":true,"given":"Christos","family":"Toumpanakis","sequence":"additional","affiliation":[{"name":"Neuroendocrine Tumour Unit, ENETS Centre of Excellence, Royal Free Hospital 1 , ,","place":["London, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4223-9736","authenticated-orcid":true,"given":"Bernard","family":"Khoo","sequence":"additional","affiliation":[{"name":"Neuroendocrine Tumour Unit, ENETS Centre of Excellence, Royal Free Hospital 1 , ,","place":["London, UK"]},{"name":"Department of Diabetes and Endocrinology, Royal Free Hospital 2 , ,","place":["London, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","published-online":{"date-parts":[[2025,9,25]]},"reference":[{"key":"2026070713310112000_bib1","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1245\/s10434-020-08220-3","article-title":"Update on pheochromocytoma and paraganglioma from the SSO endocrine\/head and neck disease-site work group. Part 1 of 2: advances in pathogenesis and diagnosis of pheochromocytoma and paraganglioma","volume":"27","author":"Patel","year":"2020","journal-title":"Ann Surg Oncol"},{"key":"2026070713310112000_bib2","doi-asserted-by":"crossref","first-page":"211","DOI":"10.4158\/EP-2018-0480","article-title":"Sympathetic paraganglioma: a single-center experience from Western India","volume":"25","author":"Jaiswal","year":"2019","journal-title":"Endocr Pract"},{"key":"2026070713310112000_bib3","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1210\/endrev\/bnab019","article-title":"Personalized management of pheochromocytoma and paraganglioma","volume":"43","author":"N\u00f6lting","year":"2022","journal-title":"Endocr Rev"},{"key":"2026070713310112000_bib4","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1097\/SLA.0000000000002195","article-title":"Impact of surgical resection of the primary tumor on overall survival in patients with metastatic pheochromocytoma or sympathetic paraganglioma","volume":"268","author":"Roman-Gonzalez","year":"2018","journal-title":"Ann Surg"},{"key":"2026070713310112000_bib5","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1093\/ejendo\/lvad146","article-title":"Responses to systemic therapy in metastatic pheochromocytoma\/paraganglioma: a retrospective multicenter cohort study","volume":"189","author":"Fischer","year":"2023","journal-title":"Eur J Endocrinol"},{"key":"2026070713310112000_bib6","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1055\/a-0715-1888","article-title":"Metastatic phaeochromocytoma: spinning towards more promising treatment options","volume":"127","author":"N\u00f6lting","year":"2019","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"2026070713310112000_bib7","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1210\/clinem\/dgae252","article-title":"Approach to the patient: concept and application of targeted radiotherapy in the paraganglioma patient","volume":"109","author":"Pacak","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070713310112000_bib8","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.2967\/jnumed.120.259697","article-title":"Systemic radiopharmaceutical therapy of pheochromocytoma and paraganglioma","volume":"62","author":"Carrasquillo","year":"2021","journal-title":"J Nucl Med"},{"key":"2026070713310112000_bib9","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/cen.12341","article-title":"131I-MIBG therapy for malignant paraganglioma and phaeochromocytoma: systematic review and meta-analysis","volume":"80","author":"van Hulsteijn","year":"2014","journal-title":"Clin Endocrinol"},{"key":"2026070713310112000_bib10","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/bjc.2013.365","article-title":"Sequelae and survivorship in patients treated with 131I-MIBG therapy","volume":"109","author":"Sze","year":"2013","journal-title":"Br J Cancer"},{"key":"2026070713310112000_bib11","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.3390\/pharmaceutics15041110","article-title":"Lutathera\u00ae orphans: state of the art and future application of radioligand therapy with 177Lu-DOTATATE","volume":"15","author":"Urso","year":"2023","journal-title":"Pharmaceutics"},{"key":"2026070713310112000_bib12","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 trial of 177Lu-dotatate for midgut neuroendocrine tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"N Engl J Med"},{"key":"2026070713310112000_bib13","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.humpath.2014.11.012","article-title":"Increased SSTR2A and SSTR3 expression in succinate dehydrogenase-deficient pheochromocytomas and paragangliomas","volume":"46","author":"Elston","year":"2015","journal-title":"Hum Pathol"},{"key":"2026070713310112000_bib14","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1111\/cen.14106","article-title":"Peptide receptor radionuclide therapy in the management of advanced pheochromocytoma and paraganglioma: a systematic review and meta-analysis","volume":"91","author":"Satapathy","year":"2019","journal-title":"Clin Endocrinol"},{"key":"2026070713310112000_bib15","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1007\/s00261-018-1752-4","article-title":"Pearls and pitfalls of response evaluation criteria in solid tumors (RECIST) v1.1 non-target lesion assessment","volume":"44","author":"Morse","year":"2019","journal-title":"Abdom Radiol"},{"key":"2026070713310112000_bib16","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet Med"},{"key":"2026070713310112000_bib17","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ejca.2016.03.081","article-title":"RECIST 1.1 \u2013 update and clarification: from the RECIST committee","volume":"62","author":"Schwartz","year":"2016","journal-title":"Eur J Cancer"},{"key":"2026070713310112000_bib18","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1200\/EDBK_201441","article-title":"Tumor response assessment for precision cancer therapy: response evaluation criteria in solid tumors and beyond","volume":"38","author":"Nishino","year":"2018","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2026070713310112000_bib19","article-title":"Common Terminology Criteria for Adverse Events (CTCAE) version 5.0","author":"U.S. Department of Health and Human Services","year":"2017","journal-title":"Bethesda, MD, USA; National Cancer Institute"},{"key":"2026070713310112000_bib20","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"2026070713310112000_bib21","article-title":"Safety and efficacy of Lu-177-DOTATATE in metastatic or inoperable phaeochromocytoma\/paraganglioma-an interim analysis","volume":"64","author":"Lin","year":"2023","journal-title":"J Nucl Med"},{"key":"2026070713310112000_bib22","doi-asserted-by":"crossref","first-page":"204","DOI":"10.2967\/jnumed.122.264860","article-title":"SNMMI procedure standard\/EANM practice guideline for SSTR PET: imaging neuroendocrine tumors","volume":"64","author":"Hope","year":"2023","journal-title":"J Nucl Med"},{"key":"2026070713310112000_bib23","doi-asserted-by":"crossref","DOI":"10.1111\/jne.13461","article-title":"Assessment of response to PRRT including anatomical and molecular imaging as well as novel biomarkers","volume":"37","author":"Kong","year":"2025","journal-title":"J Neuroendocrinol"},{"key":"2026070713310112000_bib24","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1097\/RLU.0000000000004671","article-title":"Safety and efficacy of 177Lu-DOTATATE in neuroendocrine tumor patients with extensive bone disease","volume":"48","author":"Alsadik","year":"2023","journal-title":"Clin Nucl Med"},{"key":"2026070713310112000_bib25","doi-asserted-by":"crossref","first-page":"952","DOI":"10.3390\/jcm8070952","article-title":"A clinical efficacy of PRRT in patients with advanced, nonresectable, paraganglioma-pheochromocytoma, related to SDHx gene mutation","volume":"8","author":"Kolasinska-\u0106wik\u0142a","year":"2019","journal-title":"J Clin Med"},{"key":"2026070713310112000_bib26","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1275813","article-title":"Early short-term effects on catecholamine levels and pituitary function in patients with pheochromocytoma or paraganglioma treated with [177Lu]Lu-DOTA-TATE therapy","volume":"14","author":"Gubbi","year":"2023","journal-title":"Front Endocrinol"},{"key":"2026070713310112000_bib27","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s00259-017-3816-z","article-title":"Improving quality of life in patients with pancreatic neuroendocrine tumor following peptide receptor radionuclide therapy assessed by EORTC QLQ-C30","volume":"45","author":"Marinova","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2026070713310112000_bib28","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.2967\/jnumed.111.087932","article-title":"Quality of Life in 265 patients with gastroenteropancreatic or bronchial neuroendocrine tumors treated with [177Lu-DOTA0,Tyr3]octreotate","volume":"52","author":"Khan","year":"2011","journal-title":"J Nucl Med"},{"key":"2026070713310112000_bib29","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.941832","article-title":"The evolution of PRRT for the treatment of neuroendocrine tumors; what comes next?","volume":"13","author":"Harris","year":"2022","journal-title":"Front Endocrinol"},{"key":"2026070713310112000_bib30","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s13550-019-0484-y","article-title":"Concomitant 177Lu-DOTATATE and capecitabine therapy in malignant paragangliomas","volume":"9","author":"Yadav","year":"2019","journal-title":"EJNMMI Res"},{"key":"2026070713310112000_bib31","doi-asserted-by":"crossref","DOI":"10.1111\/jne.13342","article-title":"Improved health-related quality of life during peptide receptor radionuclide therapy in patients with neuroendocrine tumours","volume":"35","author":"Edfeldt","year":"2023","journal-title":"J Neuroendocrinol"},{"key":"2026070713310112000_bib32","doi-asserted-by":"crossref","DOI":"10.1111\/jne.13349","article-title":"Safety and efficacy of peptide receptor radionuclide therapy in patients with advanced pheochromocytoma and paraganglioma: a single-institution experience and review of the literature","volume":"35","author":"Tang","year":"2023","journal-title":"J Neuroendocrinol"},{"key":"2026070713310112000_bib33","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1007\/s12094-021-02622-9","article-title":"Multidisciplinary practice guidelines for the diagnosis, genetic counseling and treatment of pheochromocytomas and paragangliomas","volume":"23","author":"Garcia-Carbonero","year":"2021","journal-title":"Clin Transl Oncol"},{"key":"2026070713310112000_bib34","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/s41574-024-01024-5","article-title":"International consensus statement on the diagnosis and management of phaeochromocytoma and paraganglioma in children and adolescents","volume":"20","author":"Casey","year":"2024","journal-title":"Nat Rev Endocrinol"},{"key":"2026070713310112000_bib35","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.3390\/cancers11101505","article-title":"Current management of pheochromocytoma\/paraganglioma: a guide for the practicing clinician in the era of precision medicine","volume":"11","author":"N\u00f6lting","year":"2019","journal-title":"Cancers"}],"container-title":["Endocrine Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eo.bioscientifica.com\/view\/journals\/eo\/5\/1\/EO-25-0019.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eo.bioscientifica.com\/downloadpdf\/journals\/eo\/5\/1\/EO-25-0019.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/eo\/article-pdf\/doi\/10.1530\/EO-25-0019\/196259\/eo-25-0019.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/eo\/article-pdf\/doi\/10.1530\/EO-25-0019\/196259\/eo-25-0019.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T17:51:59Z","timestamp":1783446719000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.bioscientifica.com\/eo\/article\/5\/1\/e250019\/35030\/177Lu-DOTATATE-peptide-receptor-radionuclide"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,1]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1,1]]}},"URL":"https:\/\/doi.org\/10.1530\/eo-25-0019","relation":{},"ISSN":["2634-4793"],"issn-type":[{"value":"2634-4793","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,1]]},"article-number":"e250019"}}